NCT00211913View on ClinicalTrials.gov

StaphVAX in Cardiovascular Surgery Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

October 31, 2005

Study Completion Date

January 31, 2006

Conditions
Staphylococcal InfectionsCardiovascular DiseasesCardiovascular Surgical Procedures
Interventions
BIOLOGICAL

S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate

single IM dose totalling 200 mcg of conjugate

BIOLOGICAL

placebo

single IM dose

Trial Locations (1)

23507

Clinical Research Associates of Tidewater, Norfolk

Sponsors
All Listed Sponsors
lead

Nabi Biopharmaceuticals

INDUSTRY

NCT00211913 - StaphVAX in Cardiovascular Surgery Patients | Biotech Hunter | Biotech Hunter